GSK3B and type 2 diabetes mellitus: We verified that decreased BMAL1 upregulated GSK-3β and inhibited Wnt/β-catenin pathway in type 2 diabetic rat models, leading to the decreased osteogenic ability of diabetic GK BMSCs (Li et al., 2017).